BCL2 and exocrine pancreatic carcinoma: Similarly, cooperativity between XIAP inhibitors and TRAIL resulted in a strong apoptotic response in pancreatic carcinoma or leukemia cells, capable to even overcome a Bcl-2-mediated resistance [51,52].